To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: ADA CONFERENCE: Muse Achieves 60% Efficacy In Diabetic Men URL: http://www.pslgroup.com/dg/86892.htm Doctor's Guide June 16, 1998
MOUNTAIN VIEW, CA -- June 16, 1998 -- An independent study shows that Vivus, Inc.'s Muse(R) (alprostadil) achieved a 60 percent efficacy rate in diabetic men with erectile dysfunction. The abstract was presented at the American Diabetes Association annual meeting in Chicago which concluded today. The 230 person study included 65 diabetic and 165 non-diabetic men with erectile dysfunction who received Muse for up to six months. Prior to Muse dosing, patients had a 30 to 45 minute counselling session that included a video on the proper administration of Muse. The treatment was deemed successful when patients completed sexual intercourse on two or more occasions. The researchers reported that 60 percent of the diabetic patients had success compared to 54 percent of non-diabetic patients. It is estimated that half of the approximately four million men with diabetes mellitus in the United States will experience erectile dysfunction. "Muse is a good treatment option for men with diabetes and/or vascular disease especially because it has few systemic side effects," said Kenneth Snow, MD, medical director of the Joslin-Lahey Diabetes & Endocrinology Center in Peabody, MA and a lead investigator in this trial. The authors also concluded that Muse appears to be more effective in men over the age of 50 and perhaps more effective in men with organic risk factors, as opposed to psychological factors. Approximately 80 percent of all cases of erectile dysfunction are believed to have a physiological origin. The investigators also noted that patient education is critical to the success of the treatment. More information on: Muse, Vivus, Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.